Randomized, Controlled Trial of Topical Exit-Site Application of Honey (Medihoney) versus Mupirocin for the Prevention of Catheter-Associated Infections in Hemodialysis Patients
Open Access
- 1 May 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 16 (5) , 1456-1462
- https://doi.org/10.1681/asn.2004110997
Abstract
The clinical usefulness of hemodialysis catheters is limited by increased infectious morbidity and mortality. Topical antiseptic agents, such as mupirocin, are effective at reducing this risk but have been reported to select for antibiotic-resistant strains. The aim of the present study was to determine the efficacy and the safety of exit-site application of a standardized antibacterial honey versus mupirocin in preventing catheter-associated infections. A randomized, controlled trial was performed comparing the effect of thrice-weekly exit-site application of Medihoney versus mupirocin on infection rates in patients who were receiving hemodialysis via tunneled, cuffed central venous catheters. A total of 101 patients were enrolled. The incidences of catheter-associated bacteremias in honey-treated (n = 51) and mupirocin-treated (n = 50) patients were comparable (0.97 versus 0.85 episodes per 1000 catheter-days, respectively; NS). On Cox proportional hazards model analysis, the use of honey was not significantly associated with bacteremia-free survival (unadjusted hazard ratio, 0.94; 95% confidence interval, 0.27 to 3.24; P = 0.92). No exit-site infections occurred. During the study period, 2% of staphylococcal isolates within the hospital were mupirocin resistant. Thrice-weekly application of standardized antibacterial honey to hemodialysis catheter exit sites was safe, cheap, and effective and resulted in a comparable rate of catheter-associated infection to that obtained with mupirocin (although the study was not adequately powered to assess therapeutic equivalence). The effectiveness of honey against antibiotic-resistant microorganisms and its low likelihood of selecting for further resistant strains suggest that this agent may represent a satisfactory alternative means of chemoprophylaxis in patients with central venous catheters.Keywords
This publication has 34 references indexed in Scilit:
- Honey in the Management of InfectionsSurgical Infections, 2003
- Honey stimulates inflammatory cytokine production from monocytesCytokine, 2003
- Editorial boardAmerican Journal of Kidney Diseases, 2003
- The Efficacy of Honey in Inhibiting Strains of Pseudomonas Aeruginosa From Infected BurnsJournal of Burn Care & Rehabilitation, 2002
- Vascular access and increased risk of death among hemodialysis patientsKidney International, 2002
- Type of vascular access and mortality in U.S. hemodialysis patientsKidney International, 2001
- III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: Update 2000American Journal of Kidney Diseases, 2001
- A comparison of the sensitivity of wound‐infecting species of bacteria to the antibacterial activity of manuka honey and other honeyJournal of Applied Bacteriology, 1992
- The antimicrobial spectrum of honey and its clinical significanceInfection, 1992
- A Semiquantitative Culture Method for Identifying Intravenous-Catheter-Related InfectionNew England Journal of Medicine, 1977